Table. Baseline Characteristics by Year of Diagnosis Among Men Diagnosed as Having Localized Prostate Cancer in the United States From 2010 to 2015 in the SEER Prostate Active Surveillance/Watchful Waiting Databasea.
| Characteristics | Overall (N = 164 760) | Year | |||||
|---|---|---|---|---|---|---|---|
| 2010 (n = 31 355) | 2011 (n = 31 916) | 2012 (n = 26 653) | 2013 (n = 25 802) | 2014 (n = 23 894) | 2015 (n = 25 140) | ||
| Initial management type, No. (%) | |||||||
| Active surveillance or watchful waiting | 20 879 (12.7) | 2542 (8.11) | 3187 (10.0) | 3362 (12.6) | 4139 (16.0) | 3684 (15.4) | 3965 (15.8) |
| Radical prostatectomy | 75 531 (45.8) | 15 031 (47.9) | 15 205 (47.6) | 12 300 (46.2) | 11 343 (44.0) | 10 591 (44.3) | 11 061 (44.0) |
| Radiotherapy | 68 350 (41.5) | 13 782 (44.0) | 13 524 (42.4) | 10 991 (41.2) | 10 320 (40.0) | 9619 (40.3) | 10 114 (40.2) |
| NCCN risk category, No. (%) | |||||||
| Low risk | 50 302 (30.5) | 10 724 (34.2) | 10 791 (33.8) | 8491 (31.9) | 7737 (30.0) | 6400 (26.8) | 6159 (24.5) |
| Intermediate risk | 81 836 (49.7) | 15 241 (48.6) | 15 620 (48.9) | 13 164 (49.4) | 12 889 (50.0) | 12 076 (50.5) | 12 846 (51.1) |
| High risk | 32 622 (19.8) | 5390 (17.2) | 5505 (17.2) | 4998 (18.8) | 5176 (20.1) | 5418 (22.7) | 6135 (24.4) |
| Prostate-specific antigen level, median (IQR), ng/mL | 6.2 (4.7-9.2) | 6.0 (4.6-8.8) | 6.0 (4.6-8.6) | 6.1 (4.7-9.0) | 6.3 (4.8-9.3) | 6.5 (4.8-9.7) | 6.7 (5.0-10.1) |
| Positive cores, No. (%) | |||||||
| ≥3 | 79 184 (48.1) | 13 475 (43.0) | 12 740 (39.9) | 12 973 (48.7) | 12 753 (49.4) | 12 873 (53.9) | 14 370 (57.2) |
| ≤2 | 47 812 (29.0) | 9215 (29.4) | 8767 (27.5) | 8154 (30.6) | 7930 (30.7) | 6834 (28.6) | 6912 (27.5) |
| Unknown | 37 764 (22.9) | 8665 (27.6) | 10 409 (32.6) | 5526 (20.7) | 5119 (19.8) | 4187 (17.5) | 3858 (15.4) |
| Age, median (IQR), y | 64 (59-70) | 64 (58-70) | 64 (58-69) | 64 (58-69) | 65 (59-69) | 65 (59-70) | 65 (59-70) |
| Race, No. (%)b | |||||||
| Black | 26 616 (16.2) | 4856 (15.5) | 4863 (15.2) | 4363 (16.4) | 4318 (16.7) | 4013 (16.8) | 4203 (16.7) |
| Other | 138 144 (83.8) | 26 499 (84.5) | 27 053 (84.8) | 22 290 (83.6) | 21 484 (83.3) | 19 881 (83.2) | 20 937 (83.3) |
Abbreviations: IQR, interquartile range; NCCN, National Comprehensive Cancer Network; SEER, Surveillance, Epidemiology, and End Results.
a
P < .05 for all patient characteristics across years 2010-2015. Percentages may not add to 100% because of rounding.
b
Race was defined via the SEER race recode variable as black vs other (including white, other, and unknown race) for the purposes of this study. Race was collected and documented by SEER registries via information from medical records, face sheets (patients’ 1-page clinical information summary), clinician notes, photographs, and any other medical record sources available to registries.